The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.

The purpose of the present invention is to develop a biomarker that better reflects thrombus formation in vivo, and to provide a method that enables risk assessment of cancer-associated thrombosis in the perioperative period of cancer patients. The method includes a step of measuring the concentration of soluble CLEC2 in blood collected from the cancer patients.

The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs.

As a technique for specifically detecting cancer cells, provided is a method for detecting cancer cells, including the steps of: bringing BC2LCN lectin into contact with a test sample; and determining the presence or absence or the amount of a sugar chain having a BC2LCN lectin binding activity in the test sample, in which the test sample is a body fluid sample of a test individual.

The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.

The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.

The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.

Described is a method of diagnosing, treating, or monitoring a treatment for Kawasaki disease in a subject. The method includes detecting the level of a biomarker in a sample obtained from the subject, the biomarker being IL-7F, sCD40L, MPIF-1, E-selectin, IP-10, or IL-33. The level is compared to a cut-off level. Also described is a kit for carrying out the method.

A method of diagnosing long-COVID in a subject, the method comprising: (a) measuring the level of one or more biomarkers in a test sample obtained from the subject, and (b) comparing the level of the one or more biomarkers in the test sample with a healthy control and/or an acute COVID-19 reference level value of said one or more biomarkers, wherein an increase in the level of the one or more biomarkers in the test sample relative to the healthy control and/or acute COVID-19 reference level value of said one or more biomarkers is indicative of long-COVID diagnosis, and wherein the one or more biomarkers are selected from Table 5. In one embodiment, the one or more biomarkers include ANG-1, P-Sel and MMP-1. A method of treating long-COVID comprising administering to a subject one or more of the biomarkers are selected from Table 5.

The device comprises a substrate comprising a first zone (1) on which is absorbed a protein capable of binding to a first membrane molecule and comprising a second zone (2), on which an antibody is absorbed, targeting a second membrane molecule, the first zone and the second zone extending together in length over a dimension comparable to the length of a cell.